ADRO:NSD-Aduro Biotech, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.00

Change

0.00 (0.00)%

Market Cap

USD 0.24B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


ADRO Stock Forecast & Price:
Based on the Aduro Biotech, Inc stock forecasts from 0 analysts, the average analyst target price for Aduro Biotech, Inc is not available over the next 12 months. Aduro Biotech, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Aduro Biotech, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Aduro Biotech, Inc’s stock price was USD 0.00. Aduro Biotech, Inc’s stock price has changed by 0% over the past week, 0% over the past month and 0% over the last year.

No recent analyst target price found for Aduro Biotech, Inc
No recent average analyst rating found for Aduro Biotech, Inc

About Aduro Biotech, Inc (ADRO:NSD)

Aduro Biotech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I do ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-06-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-11.15 (-3.88%)

USD74.82B 30.88 20.19
REGN Regeneron Pharmaceuticals Inc

-7.98 (-1.32%)

USD67.28B 8.71 6.35
MRNA Moderna Inc

-3.17 (-2.18%)

USD57.82B 4.27 2.57
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.74 (+0.42%)

USD33.01B 55.02 44.86
BNTX BioNTech SE

-3.89 (-2.71%)

USD32.57B 2.40 1.28
RPRX Royalty Pharma Plc

-0.27 (-0.63%)

USD29.12B 31.56 15.41
GMAB Genmab AS

-0.95 (-2.93%)

USD21.17B 63.61 5.25
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ARGX argenx NV ADR

-9.00 (-2.41%)

USD19.77B N/A N/A

ETFs Containing ADRO

Symbol Name Weight Mer Price(Change) Market Cap
DVYE iShares Emerging Markets .. 0.00 % 0.49 %

-0.08 (-0.30%)

USD0.66B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 118.18% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 118.18% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 1,724.26% N/A N/A N/A N/A
Risk Adjusted Return 6.85% N/A N/A N/A N/A
Market Capitalization 0.24B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.08 N/A N/A N/A N/A
Price / Cash Flow Ratio -3.61 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -87.44% N/A N/A N/A N/A
Return on Invested Capital -87.33% N/A N/A N/A N/A
Return on Assets -13.90% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.66 N/A N/A N/A N/A
Short Percent 4.86% N/A N/A N/A N/A
Beta 0.39 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.